Vor Ort
Merkzettel Warenkorb
Produktbild: Modern Drug Synthesis

Modern Drug Synthesis

Aus der Reihe Wiley Series on Drug Synthesis

165,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

09.08.2010

Herausgeber

Jie Jack Li + weitere

Verlag

John Wiley & Sons

Seitenzahl

384

Maße (L/B/H)

26/18,3/2,4 cm

Gewicht

892 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-0-470-52583-8

Beschreibung

Rezension

"All chapters are very well written, and the used schemes and tables are conveniently arranged. The information and explanations given are strengthened by well-chosen examples and so the reader can easily follow the discussion. The comprehensive referenced literature placed at the end of each chapter enables further reading, and a detailed keyword index in combination with a logically structured Table of Content allows fast access to the topic of interest." ( ChemMedChem , 2010)

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

09.08.2010

Herausgeber

Verlag

John Wiley & Sons

Seitenzahl

384

Maße (L/B/H)

26/18,3/2,4 cm

Gewicht

892 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-0-470-52583-8

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: Modern Drug Synthesis
  • Preface.
     
    Contributors.
     
    I. Infectious Diseases.
     
    Chapter 1. Raltegravir (Isentress), The First-in-class HIV-1 Integrase Inhibitor (Julianne A. Hunt).
     
    1.1 Background.
     
    1.2 Pharmacology.
     
    1.3 Structure-Activity Relationship (SAR).
     
    1.4 Pharmacokinetics and Drug Metabolism.
     
    1.5 Efficacy and Safety.
     
    1.6 Syntheses.
     
    1.7 References.
     
    Chapter 2. Maraviroc (Selzentry), The First-in-class CCR5 Antagonist for the Treatment of HIV (David Price).
     
    2.1 Background.
     
    2.2 Structure-Activity Relationship (SAR).
     
    2.3 Pharmacokinetics and Safety.
     
    2.4 Syntheses.
     
    2.5 References.
     
    Chapter 3. Darunavir (Prezista), A HIV-1 Protease Inhibitor for Treatment of Multidrug Resistant HIV (Arun K. Ghosh and Cuthbert D. Martyr).
     
    3.1 Background.
     
    3.2 Pharmacology.
     
    3.3 Structure-Activity Relationship (SAR).
     
    3.4 Pharmacokinetics and Drug Metabolism.
     
    3.5 Efficacy and Safety.
     
    3.6 Syntheses.
     
    3.7 References.
     
    II. Cancer.
     
    Chapter 4. Decitabine (Dacogen), A DNA Methyltransferase Inhibitor for Cancer (Jennifer A. Van Camp).
     
    4.1 Background.
     
    4.2 Pharmacology.
     
    4.3 Structure-Activity Relationship (SAR).
     
    4.4 Pharmacokinetics and Drug Metabolism.
     
    4.5 Efficacy and Safety.
     
    4.6 Syntheses.
     
    4.7 References.
     
    Chapter 5. Capecitabine (Xeloda), An Oral Chemotherapy Agent (R. Jason Herr).
     
    5.1 Background.
     
    5.2 Pharmacology.
     
    5.3 Structure-Activity Relationship (SAR).
     
    5.4 Pharmacokinetics and Efficacy.
     
    5.5 Syntheses.
     
    5.6 References.
     
    Chapter 6. Sorafenib (Nexavar), A Multi-kinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma (Shuanghua Hu).
     
    6.1 Background.
     
    6.2 Pharmacology.
     
    6.3 Structure-Activity Relationship (SAR).
     
    6.4 Pharmacokinetics and Drug Metabolism.
     
    6.5 Efficacy and Safety.
     
    6.6 Syntheses.
     
    6.7 References.
     
    Chapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor (Martin Pettersson).
     
    7.1 Background.
     
    7.2 Discovery and Development.
     
    7.3 Syntheses.
     
    7.3.1 Discovery Route.
     
    7.3.2 Process Route.
     
    7.4 References.
     
    Chapter 8. Bortezomib (Velcade), A First-in-class Proteasome Inhibitor (Benjamin S. Greener and David S. Millan).
     
    8.1 Background.
     
    8.2 Pharmacology.
     
    8.3 Structure-Activity Relationship (SAR).
     
    8.4 Pharmacokinetics and Drug Metabolism.
     
    8.5 Efficacy and Safety.
     
    8.6 Syntheses.
     
    8.7 References.
     
    Chapter 9. Pazopanib (Votrient), A VEGFR Tyrosine Kinase Inhibitor for Cancer (Ji Zhang and Jie Jack Li).
     
    9.1 Background.
     
    9.2 Pharmacology.
     
    9.3 Structure-Activity Relationship (SAR).
     
    9.4 Pharmacokinetics and Drug Metabolism.
     
    9.5 Efficacy and Safety.
     
    9.6 Syntheses.
     
    9.7 Other VEGFR Inhibitors in Development: Vandetanib and Cediranib.
     
    9.8 References.
     
    III. Cardiovascular and Metabolic Diseases.
     
    Chapter 10. Sitagliptin (Januvia), A Treatment for Type 2 Diabetes (Scott D. Edmondson, Feng Xu, and Joseph D. Armstrong III).
     
    10.1 Background.
     
    10.2 Pharmacology.
     
    10.3 Structure-Activity Relationship (SAR).
     
    10.4 Pharmacokinetics and Drug Metabolism.
     
    10.5 Efficacy and Safety.
     
    10.6 Syntheses.
     
    10.7 References.
     
    Chapter 11. Aliskiren (Tekturna), The